The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

Dulce Soler, Tobias R. Chapman, Lili Yang, +3

Journal of Pharmacology and Experimental Therapeutics

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

Eric R. Fedyk, Tim Wyant, Lili Yang, +4

Inflammatory Bowel Diseases

Tuberous sclerosis complex–mediated mTORC1 overactivation promotes age-related hearing loss

Xiaolong Fu, Xiaoyang Sun, Linqing Zhang, +8

Journal of Clinical Investigation

Mtorc1 ActivityCell DeathOxidative StressSignaling PathwayDegenerative Pathology +19

Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis

Krista G. Haanstra, Sam Hofman, Dave M. Lopes Estêvão, +7

The Journal of Immunology

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

Tim Wyant, Lili Yang, Eric R. Fedyk

mAbs

Gastrointestinal PharmacologyImmunologyImmune RegulationBlood CellImmunologic Mechanism +22

MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model

Keiko Igaki, Yusaku Komoike, Yoshiki Nakamura, +7

International Immunopharmacology

InflammationCytokineImmune RegulationImmunologyChronic Inflammation +8

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab

Tim Wyant, Jose Estevam, Lili Yang, +1

Cytometry Part B Clinical Cytometry

ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

Vipul Jairath, Andrés Yarur, Mark T. Osterman, +6

Clinical Gastroenterology and Hepatology

Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials

Timothy Wyant, Lili Yang, Maria Rosario

The AAPS Journal

Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease

Timothy Wyant, Lili Yang, Richard A. Lirio, +1

The Journal of Clinical Pharmacology

Chronic Inflammatory DiseasesGastrointestinal PharmacologyImmunodeficienciesImmunologyPathology +16